Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Treatment of anemia with darbepoetin alfa in systolic heart failure.

Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ; RED-HF Committees; RED-HF Investigators.

N Engl J Med. 2013 Mar 28;368(13):1210-9. doi: 10.1056/NEJMoa1214865. Epub 2013 Mar 10.

2.

Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF).

McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Solomon SD, Tendera M, van Veldhuisen DJ, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB; RED-HF Committees Investigators.

Eur J Heart Fail. 2013 Mar;15(3):334-41. doi: 10.1093/eurjhf/hfs204. Epub 2013 Jan 17.

3.

Impact on health-related quality of life in kidney transplant recipients with late posttransplant anemia administered darbepoetin alfa: results from the STRATA study.

Bloom RD, Bolin P, Gandra SR, Scarlata D, Petersen J.

Transplant Proc. 2011 Jun;43(5):1593-600. doi: 10.1016/j.transproceed.2011.02.009.

PMID:
21693239
4.

Treatment of anemia with darbepoetin alfa in heart failure.

Abraham WT, Anand IS, Klapholz M, Ponikowski P, Scarlata D, Wasserman SM, van Veldhuisen DJ.

Congest Heart Fail. 2010 May-Jun;16(3):87-95. doi: 10.1111/j.1751-7133.2010.00142.x.

5.

Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials.

Krause MW, Raja R, Agarwal A, Silver MR, Scarlata D, Sciarra A, Kewalramani R.

Drugs Aging. 2009;26(8):665-75. doi: 10.2165/11316450-000000000-00000.

6.

A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.

Brophy GM, Sheehan V, Shapiro MJ, Lottenberg L, Scarlata D, Audhya P; ASSESS Study Group and Amgen Inc.

Clin Ther. 2008 Dec;30(12):2324-34. doi: 10.1016/j.clinthera.2008.12.024.

PMID:
19167591
7.

The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis.

Abu-Alfa AK, Sloan L, Charytan C, Sekkarie M, Scarlata D, Globe D, Audhya P.

Curr Med Res Opin. 2008 Apr;24(4):1091-100. doi: 10.1185/030079908X280653 . Epub 2008 Mar 6.

PMID:
18328118
8.

Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.

Hoggard J, Crouch T, McMurray S, Levine M, Prathikanti R, Scarlata D, Audhya P.

Curr Med Res Opin. 2006 Oct;22(10):2023-30.

PMID:
17022861
9.

Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease.

Hertel JE, Locay HR, Scarlata DS, Prathikanti R, Audhya PK.

Mayo Clin Proc. 2006 Sep;81(9):1188-94.

PMID:
16970215
11.

Impact of multidisciplinary, early renal education on vascular access placement.

Lindberg JS, Husserl FE, Ross JL, Jackson D, Scarlata D, Nussbaum J, Cohen A, Elzein H.

Nephrol News Issues. 2005 Feb;19(3):35-6, 41-3.

PMID:
15882043
12.

Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry.

Dale DC, Cottle TE, Fier CJ, Bolyard AA, Bonilla MA, Boxer LA, Cham B, Freedman MH, Kannourakis G, Kinsey SE, Davis R, Scarlata D, Schwinzer B, Zeidler C, Welte K.

Am J Hematol. 2003 Feb;72(2):82-93. Review.

13.

Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy.

Freedman MH, Bonilla MA, Fier C, Bolyard AA, Scarlata D, Boxer LA, Brown S, Cham B, Kannourakis G, Kinsey SE, Mori PG, Cottle T, Welte K, Dale DC.

Blood. 2000 Jul 15;96(2):429-36.

14.

A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials.

Kasarskis EJ, Scarlata D, Hill R, Fuller C, Stambler N, Cedarbaum JM.

J Neurol Sci. 1999 Oct 31;169(1-2):118-25.

PMID:
10540019
15.

California pediatricians' knowledge of and response to recommendations for universal infant hepatitis B immunization.

Wood DL, Rosenthal P, Scarlata D.

Arch Pediatr Adolesc Med. 1995 Jul;149(7):769-73.

PMID:
7795767
16.

Incremental prognostic value of exercise thallium-201 myocardial single-photon emission computed tomography late after coronary artery bypass surgery.

Palmas W, Bingham S, Diamond GA, Denton TA, Kiat H, Friedman JD, Scarlata D, Maddahi J, Cohen I, Berman DS.

J Am Coll Cardiol. 1995 Feb;25(2):403-9.

17.

Impact of family relocation on children's growth, development, school function, and behavior.

Wood D, Halfon N, Scarlata D, Newacheck P, Nessim S.

JAMA. 1993 Sep 15;270(11):1334-8.

PMID:
7689659
18.

Ten-year experience with the St. Jude Medical valve for primary valve replacement.

Czer LS, Chaux A, Matloff JM, DeRobertis MA, Nessim SA, Scarlata D, Khan SS, Kass RM, Tsai TP, Blanche C, et al.

J Thorac Cardiovasc Surg. 1990 Jul;100(1):44-54; discussion 54-5.

PMID:
2366564

Supplemental Content

Loading ...
Support Center